Found: 8
Select item for more details and to access through your institution.
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 6, p. e496, doi. 10.1111/jdv.19681
- By:
- Publication type:
- Article
Secukinumab versus guselkumab in the complete resolution of ustekinumab‐resistant psoriatic plaques: The ARROW study.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 10, p. 1834, doi. 10.1111/exd.14828
- By:
- Publication type:
- Article
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 5, p. 821, doi. 10.1007/s40257-023-00782-8
- By:
- Publication type:
- Article
Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 781, doi. 10.1007/s40259-022-00558-2
- By:
- Publication type:
- Article
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 233, doi. 10.1007/s13555-021-00654-1
- By:
- Publication type:
- Article
Association Between Baseline Disease Characteristics and Relapse-Free Survival (RFS) in Patients (pts) with BRAF V600--Mutant Resected Stage III Melanoma Treated with Adjuvant Dabrafenib (D) + Trametinib (T) or Placebo (PBO).
- Published in:
- Journal of Oncology Navigation & Survivorship, 2019, v. 10, n. 11, p. 500
- By:
- Publication type:
- Article
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
- Published in:
- International Journal of Hematology, 2014, v. 99, n. 5, p. 616, doi. 10.1007/s12185-014-1566-2
- By:
- Publication type:
- Article
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
- Published in:
- 2014
- By:
- Publication type:
- journal article